Results
CF33-hNIS-antiPDL1 killed PDAC cells in a dose-dependent manner achieving >90% cell killing by day 8. Cells infected with CF33-hNIS-antiPDL1 produced bioactive anti-PD-L1 antibody which blocked PD-1/PD-L1 interaction.In vivo, single dose of virus reduced tumor burden and prolonged survival of treated mice. It was observed that IP administration of CF33-hNIS-antiPDL1 was more effective than IV administration.
"achieving >90% cell killing by day 8"
I know it is just a lab trial yet no annoucement on ASX.
Latest Email from Leslie (11 Feb 2020 @ 9am), page-6
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $418.9M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.4¢ | $461.9K | 8.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1082545 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 603058 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |